Breaking News
January 24, 2018 - Study illustrates role of specific antibodies in protection against influenza
January 24, 2018 - Curcumin could provide meaningful cognitive benefits, study suggests
January 24, 2018 - Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
January 24, 2018 - EndoBreak: Obesity in 2018; Diabetes Risks in Pregnancy
January 24, 2018 - Recommendations to improve the quality of ultrasound imaging in obstetrics and gynecology
January 24, 2018 - Sensory feedback facilitates enhanced brainwave control of portable hand-exoskeleton
January 24, 2018 - Innovative system helps medical staff to accurately evaluate patients’ risk of falling
January 24, 2018 - Porvair Sciences to showcase microplate and chromatography products at Analytica 2018
January 24, 2018 - Children with cochlear implant learn words faster than kids with normal hearing
January 24, 2018 - Ionis’ Inotersen NDA Accepted for Priority Review by the FDA
January 24, 2018 - Abuse-Deterrent Opioid No Help in Australia
January 24, 2018 - Maternal mortality rates are on the rise, but more accurate estimates are needed
January 24, 2018 - New essential oil inhaler facilitates pain management
January 24, 2018 - USPSTF: Insufficient Evidence to Screen Kids for Scoliosis
January 24, 2018 - Team develops method to identify seizure-causing regions in the brain
January 24, 2018 - New report takes comprehensive look at health effects of e-cigarettes
January 24, 2018 - Researchers develop new indicator for assessing active aging
January 24, 2018 - Research highlights decreasing trend in traditional hysterectomy
January 24, 2018 - Computer-based speech analysis has potential to improve prediction of psychosis
January 24, 2018 - New family of FFPE reagent kits launched by Beckman Coulter Life Sciences
January 24, 2018 - Researchers use epigenetic signatures to advance diagnosis for neurodevelopmental disorders
January 24, 2018 - EPI report reveals air quality as major environmental threat to public health
January 23, 2018 - How to Fight the Flu This Season
January 23, 2018 - Mixed Data for Fatty Acid Intake and Glaucoma
January 23, 2018 - The brains of jazz and classical pianists work differently
January 23, 2018 - Scientists identify protein biomarkers to track patients with Hutchinson-Gilford progeria syndrome
January 23, 2018 - Exercise could extend the life expectancy of breast cancer survivors, study states
January 23, 2018 - Researchers show association between microbiome and cancer-related blood infections
January 23, 2018 - Cancer.com Site Sat Dormant for 10 Years. Now It’s Live Again.
January 23, 2018 - FDA’s program to speed up drug approval shaved nearly a year off the process
January 23, 2018 - Study reveals key challenges and frustrations associated with current RTSM/IRT solutions
January 23, 2018 - Researchers unravel function of protein ‘smallish’
January 23, 2018 - Infants born in withdrawal due to opioid exposure in utero show abnormalities
January 23, 2018 - Researchers block common siren call of glioblastoma and metastatic breast cancer
January 23, 2018 - FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
January 23, 2018 - Six Concerns About Practice Consolidation
January 23, 2018 - How Alzheimer’s Changes the Brain
January 23, 2018 - Pharmaceutical stirs outrage over price hike for brain tumor drug
January 23, 2018 - University under fire for off-the-grid herpes vaccine experiments
January 23, 2018 - Gastric environment permanently changes in the presence of Helicobacter pylori infection
January 23, 2018 - Scientists take tissue-engineering approach to improve healing related to skeletal system
January 23, 2018 - Consumption of dietary fiber can prevent obesity and metabolic syndrome, study shows
January 23, 2018 - FDA Alert: Multiple Drug Products by Flawless Beauty: Recall
January 23, 2018 - Rhymes with Amyloid: That’s Improbable!
January 23, 2018 - CLCN2-related leukoencephalopathy – Genetics Home Reference
January 23, 2018 - Can road salt and other pollutants disrupt our circadian rhythms?
January 23, 2018 - ‘Depression literacy’ program encourages many teens to seek adult help
January 23, 2018 - New initiative seeks to transform the way people live with dementia
January 23, 2018 - Isosec introduces first Virtual Smartcard for NHS Trusts and clinicians
January 23, 2018 - New report reveals rapid growth in Vietnam pharmaceutical market
January 23, 2018 - Obamacare Led to Rise in Breast Cancer Screening
January 23, 2018 - Bariatric Tx Bests Usual Care for Long-Term Health
January 23, 2018 - Keep Your Dogs and Cats Safe From Holiday Hazards
January 23, 2018 - New AI technology significantly improves human kidney analysis
January 23, 2018 - In Trump’s first year, anti-abortion forces make strides despite setbacks
January 23, 2018 - Small PFS Bump in Gastric/GEJ Cancer
January 23, 2018 - Defending against environmental stressors may shorten lifespan
January 23, 2018 - Researchers create cavitation bubbles to remove dental plaque
January 23, 2018 - Discovery offers fresh perspective on how the brain keeps its balance
January 23, 2018 - Opioid exposure linked to physical abnormalities in newborns
January 23, 2018 - Study identifies genes involved in latent asymptomatic state of breast cancer metastases
January 23, 2018 - Kala Pharmaceuticals Announces New Drug Application for Inveltys (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration
January 23, 2018 - Closer Look at Household Contacts Finds More TB Cases
January 23, 2018 - Type 1 IFNs may mediate Zika pregnancy complications
January 23, 2018 - Anti-inflammatory pill could help make vaccines more effective for the elderly
January 23, 2018 - New discovery sheds light on iron-restricted anemia that causes fatigue in millions
January 23, 2018 - BMG LABTECH’s Australian office celebrates 20 years of innovation and growth in APAC region
January 23, 2018 - FDA Alert: Basic Drugs Brand of Senna Laxative by Magno-Humphries Laboratories: Recall
January 23, 2018 - Chronic Opioid Use High Among IBD Patients
January 23, 2018 - New long-acting, less-toxic HIV drug suppresses virus in humanized mice
January 23, 2018 - Findings provide better understanding of cognitive inflexibility in Fragile X Syndrome
January 23, 2018 - Powerful anti-oxidant can stop progression of fatty liver disease in young mice
January 23, 2018 - Marijuana use does not lower probability of conception, study shows
January 23, 2018 - Study shows value of occupational therapy in the lives of young adults with diabetes
January 23, 2018 - Chinese researchers develop multifunctional vehicle to transport gene therapeutics
January 23, 2018 - Researchers seek to understand effect of very low birth weight on the brain
January 23, 2018 - Be a Savvy Supermarket Shopper
January 23, 2018 - NIH Striving to Avoid False Hope in Chronic Fatigue
January 23, 2018 - ClinicalTrials.gov: Occupational Stress
January 23, 2018 - PrEP could make US easily hit its 2020 HIV prevention goal, study finds
No Efficacy Hit from Stopping Immunotherapy for AEs

No Efficacy Hit from Stopping Immunotherapy for AEs

image_pdfDownload PDFimage_print

Action Points

  • Efficacy outcomes were similar between patients who discontinued melanoma induction immunotherapy with nivolumab plus ipilimumab due to adverse events (AEs), and those who did not discontinue therapy.
  • Note that these pooled trial data suggest patients may continue to derive benefit even after treatment is stopped because of AEs, and response rate, depth of response, and overall survival do not seem to be diminished for these patients.

Patients who discontinued induction immunotherapy for advanced melanoma because of adverse events did just as well as those who continued treatment uninterrupted, a pooled analysis of randomized trials showed.

Patients who discontinued had an objective response rate of almost 60% compared with about 50% for those who finished induction therapy. Median progression-free survival (PFS) did not differ significantly between patients who discontinued and those who did not; median overall survival had yet to be reached in either group.

“Most patients who discontinued the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did so before receiving all four doses of the combination,” Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues concluded in the Journal of Clinical Oncology.

“Efficacy of nivolumab plus ipilimumab seemed to be similar for those who did and did not discontinue because of adverse events. This suggests that patients may continue to derive benefit from combination therapy even after treatment is stopped because of adverse events.”

Despite the preliminary nature of the data, the findings raised “thought-provoking questions about the possible impact of early treatment cessation in the setting of toxicity on the durability of response,” two Australian oncologists wrote in an accompanying editorial.

“Several key messages ave arisen from this work,” said Matteo S. Carlino, MD, of the University of Sydney, and Shaneen Sandhu, MD, of Peter MacCallum Cancer Center and the University of Melbourne, in the editorial. “The response rate, depth of response, and overall survival do not seem to be diminished for patients who discontinue treatment as a result of immune-related adverse events at induction.

“In addition, the use of immunomodulatory agents to manage checkpoint inhibitor-related toxicities does not seem to hinder responses or durability of responses in the majority of patients who discontinue treatment because of immune-related adverse events at induction. The merits, liability, and optimal duration of ongoing anti-PD-1 therapy after discontinuing induction therapy because of immune-related adverse events will require prospective evaluation.”

The predictive utility of early-onset immune-related adverse events also requires further study, Carlino and Sandhu added.

Clinical trials of combined nivolumab-ipilimumab therapy for advanced melanoma showed that about 40% of patients discontinued induction therapy with the combination because of therapy-related adverse events. Most patients stopped before receiving the recommended four doses of therapy. The impact of early discontinuation on clinical outcomes remained unclear.

To investigate the impact of early discontinuation on outcomes, Postow and colleagues pooled data from randomized phase II and III trials involving a total of 409 patients with advanced melanoma treated with the combination of nivolumab and ipilimumab. Investigators compared treatment efficacy in 96 patients who discontinued treatment during the induction phase of therapy because of adverse events and in 233 patients who did not discontinue because of adverse events.

Investigators evaluated the safety of the combination in patients who discontinued treatment at any time because of adverse events versus those who who did not.

After a minimum follow-up for efficacy of 18 months, median PFS was 8.4 months (95% CI 5.8-16.7) in patients who discontinued induction therapy because of adverse events and 10.8 months (95% CI 5.9-23.0) in those who did not discontinue during induction therapy (P=0.97). The 18-month PFS was 38% in the patients who discontinued and 49% for those who did not. Median PFS had yet to be reached in either group (HR 0.79, 95% CI 0.54-1.17, P=0.2344).

The 18-month overall survival was 67% for patients who discontinued induction therapy because of adverse events and 62% for those who did not.

The objective response rate also did not differ significantly between patients who discontinued because of adverse events (58.3%) and patients who did not (50.2%).

The safety analysis showed that 156 of 407 (38%) patients discontinued treatment at any time because of adverse events, most of which were grade 3/4 severity. Colitis was the most common adverse event leading to discontinuation (10%), followed by elevated liver enzymes (4% to 5%). Colitis also was the most common serious adverse event leading to hospitalization (21% of all patients who discontinued treatment because of adverse events).

The most frequent grade 3/4 treatment-related adverse events associated with discontinuation at any time were gastrointestinal (especially diarrhea and colitis, 20% each). For patients who did not discontinue because of adverse events, the most common grade 3/4 adverse events were hepatic (10%).

Systemic corticosteroids were the most frequently used immunosuppressive therapy for management of adverse events, administered to 91% of patients who discontinued nivolumab-ipilimumab combination therapy because of adverse events and 55% of those who did not discontinue.

The study was supported by Bristol-Myers Squibb and the National Cancer Institute.

Postow disclosed relationships with Bristol-Myers Squibb, Marck, Amgen, Novartis, Array BioPharma, Infinity Pharmaceuticals, and RGenix. All of the coauthors disclosed relationships with one or more healthcare industry company.

Carlino disclosed relationships with Bristol-Myers Squibb, Merck, Amgen, Novartis, and Pierre Fabre. Sandhu disclosed relationships with Merck, Bristol-Myers Squibb, Amgen, and Janssen.

2017-10-24T14:30:00-0400

Tagged with:

About author

Related Articles